|
Treatment of Non-Hodgkin's Lymphoma with 90Y-hLL2 IgG Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Treatment of Non-Hodgkin's Lymphoma with 90Y-hLL2 IgG conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Treatment of Non-Hodgkin's Lymphoma with 90Y-hLL2 IgG Clinical research trials and Treatment of Non-Hodgkin's Lymphoma with 90Y-hLL2 IgG healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Treatment of Non-Hodgkin's Lymphoma with 90Y-hLL2 IgG. Treatment of Non-Hodgkin's Lymphoma with 90Y-hLL2 IgG Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Treatment of Non-Hodgkin's Lymphoma with 90Y-hLL2 IgG clinical trial. Human subjects often receive the most effective healthcare possible for their Treatment of Non-Hodgkin's Lymphoma with 90Y-hLL2 IgG condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > Treatment of Non-Hodgkin's Lymphoma with 90Y-hLL2 IgG  Treatment of Non-Hodgkin's Lymphoma with 90Y-hLL2 IgG
Treatment of Non-Hodgkin's Lymphoma with 90Y-hLL2 IgG
For Condition: Lymphoma, B-Cell,Non-Hodgkin's Lymphoma
Status: No longer recruiting
Sponsor(s): Immunomedics, Inc. ,
Synopsis: The purpose of this trial is to determine the safety of a 90Y-radiolabeled, humanized (CDR-grafted) form of the LL2 monoclonal antibody in patients with Non-Hodgkin's lymphoma (NHL) at different dose levels.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion: - Histological or cytological diagnosis of B-cell lymphoma, and has failed at least one regimen of standard chemotherapy. (All histological grades of NHL will be eligible for this trial.) - Measureable via CT, with at least one lesion > or = 1.5cm in one or both dimensions. (Splenic tumors in absence of other tumors will not qualify.) - Radiological studies (ie - CT) must be performed within 4 weeks prior to study start. - Acceptable tumor burgen that will allow adequate follow-up and evaluation. - Less that 25% bone marrow involvement, determined by bone marrow biopsy. - Must observe the following washout periods: At least 4 weeks beyond any major surgery. At least 4 weeks beyond any radiation therapy to the index lesion, and has recovered from radiation-induced toxicity. At least 4 weeks beyond chemotherapy and/or immunotherapy. At least 2 weeks beyond corticosteriod(s) use and blood counts are with laboratory criteria. - Must have Karnofsky score >70% (or equivalent, ECOG 0-2) with expected survival of at least 6 months. - Serum creatinine < or = 1.5mg/dl or creatinine clearance > or = 50ml/min. - Serum bilirubin < or = 2mg/dl. - Hemoglobin > or = 10 g/dl; WBC > or = 3000/mm3; granulocyte count > or = 150/mm3; platelet count > or = 100,000/mm3 with out transfusions or cytokines for at least 30 days prior to study. - Immunomedics ELISA assay of HahLL2 < 100ng/ml for those with prior history of monoclonal antibody infusions. - Cognizant informed consent.
Total Enrollment:
Location and Contact Information:
Additional Information:
Study ID Numbers: IM-T-hLL2-06;
Study Start Date: August 2000
Record last reviewed: May 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00061425
Other Lymphoma, B-Cell Studies:
1. A Safety/Efficacy Study of SGN-30 (Antibody) in Patients with Refractory or Recurrent CD30+ Hematologic Malignancies
2. Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies
3. Treatment of Non-Hodgkin's Lymphoma with 90Y-hLL2 IgG
4. Phase II Study of Proteasome Inhibitor PS-341 For Patients With Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy
5. Avastin Plus Rituximab for Patients with Relapsed and Chemotherapy - or Rituxan-Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Related Studies:
Other Lymphoma, B-Cell Clinical Trials
Other Clinical Trials
Other Clinical Trials
Treatment of Non-Hodgkin's Lymphoma with 90Y-hLL2 IgG
|
|
|
|
|
|
|
|
